🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Ivabradine + Usual Care

    The University of Hong Kong

    Atrial Fibrillation (Permanent)

    approved small molecule active

    1 trial

  2. JZP258 (XYWAV)

    Jazz Pharmaceuticals Ireland Limited

    Idiopathic Hypersomnia

    approved small molecule completed

    1 trial

  3. KENACORT 40 mg/ml sospensione iniettabile, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio, Lidocaína B. Braun 20 mg/ml solución inyectable, BUPIVACAÍNA PHYSAN 0,25% SOLUCIÓN INYECTABLE

    The George Institute

    TRAPEZIUS MYOFASCIAL SYNDROME IN FIBROMYALGIA PATIENTS

    approved small molecule active

    1 trial

  4. Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kalydeco 75 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets

    Istituto Gentili S.r.l.

    Cystic Fibrosis

    approved small molecule active

    1 trial

  5. Kanglaite Injection+Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    approved small molecule active

    1 trial

  6. Kenacort-A 10, suspensie voor injectie 10 mg/ml, Kenacort-T 40 mg/ml injektionsvätska, suspension

    Disc Medicine

    Strictures after esophageal atresia repair

    approved small molecule active

    1 trial

  7. Kesimpta 20 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Relapsing forms of Multiple Sclerosis (RMS)

    approved small molecule active

    1 trial

  8. Ketamine

    Teva Pharma GmbH

    Treatment Resistant Depression

    approved small molecule active

    1 trial

  9. Ketamine Hydrochloride

    NORTHWEST BIOTHERAPEUTICS INC

    Revision Spine Surgery

    approved small molecule active

    1 trial

  10. Ketanest® S 25 mg/ml - Ampullen, Ketanest® S 5 mg/ml - Ampullen

    Disc Medicine

    Complex regional pain syndrome

    approved small molecule active

    1 trial

  11. Ketorolac Injection

    United Therapeutics Europe Ltd

    Orthopaedic Trauma

    approved small molecule active

    1 trial

  12. Keverprazan

    The First People's Hospital of Lianyungang

    H. Pylori Infection

    approved small molecule active

    1 trial

  13. Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.

    Disc Medicine

    autoimmune disorders, joint disorders synonym: Still's disease, systemic JIA

    approved small molecule active

    1 trial

  14. Kuvan

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    approved small molecule completed

    2 trials

  15. Kuvan®

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    approved small molecule completed

    2 trials

  16. L. helveticus R0052 and B. longum R0175

    Acadia Pharmaceuticals B.V.

    Attention Deficit Hyperactivity Disorder

    approved other active

    1 trial

  17. LABA/LAMA or Placebo inhalation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchiectasis Adult

    approved small molecule active

    1 trial

  18. LACTOSE MONOHYDRATE, Clopidogrel Viatris 75 mg film coated tablets, Acetylsalicylzuur Aurobindo cardio 80 mg, tabletten., Clopidogrel Zentiva 75 mg film-coated tablets

    Disc Medicine

    (Chronic) Peripheral (occlusive) arterial disease (PAD)

    approved small molecule active

    1 trial

  19. LCS® Complete™ Mobile Bearing Knee Systems

    International Peace Maternity and Child Health Hospital

    Knee Osteoarthritis

    approved other completed

    1 trial

  20. LENVATINIB, NIVOLUMAB, CABOZANTINIB, LENVATINIB, NIVOLUMAB, AXITINIB, CABOZANTINIB, PEMBROLIZUMAB, IPILIMUMAB, AXITINIB, AXITINIB

    Fondazione Telethon ETS

    metastatic or locally advanced renal cell carcinoma

    approved small molecule active

    1 trial

  21. LIVTENCITY 200 mg film-coated tablets.

    The George Institute

    Transplant patients with high recurrent Epstein-Barr infection

    approved small molecule active

    1 trial

  22. LNG-IUS

    Hospital Authority, Hong Kong

    Endometriosis

    approved small molecule completed

    1 trial

  23. Lansoprazole

    Takeda

    Functional Dyspepsia

    approved small molecule terminated

    1 trial

  24. Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution

    NovoThirteen

    Type 2 diabetes

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources